Related Experiment Video
Updated: Feb 25, 2026

09:27
Automation of Bio-Atomic Force Microscope Measurements on Hundreds of C. albicans Cells
Published on: April 2, 2021
4.4K
Plasma concentrations of caspofungin in a critically ill patient with morbid obesity
Rafael Ferriols-Lisart1, Gerardo Aguilar2, Alejandro Pérez-Pitarch3
1Department of Pharmacy, University Clinical Hospital of Valencia, Avda. Blasco Ibañez 17, Valencia, Spain. ferriols_raf@gva.es.
Critical Care (London, England)
|August 3, 2017
Abstract
No abstract available in PubMed .
Related Concept Videos
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
322
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
322
Drug Dosing: Obese Patients
314
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
314
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
247
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
247
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
52
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
52
Fungal Phylum Microsporidia
606
Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
606
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
298
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
298

